MS1819 Plus PERT Improved Fat Absorption in Severe EPI

MS1819 Plus PERT Improved Fat Absorption in Severe EPI

303384

MS1819 Plus PERT Improved Fat Absorption in Severe EPI

Combining investigational therapy MS1819 with standard pancreatic enzyme replacement therapy (PERT) can improve fat absorption in people with cystic fibrosis (CF) who have severe exocrine pancreatic insufficiency (EPI), top-line results from a Phase 2 clinical trial show. “A safe and effective therapy that allows CF patients to gain control over EPI, while diminishing the daily pill burden required with PERT-based medications, is an important medical need and a significant product opportunity,” James Pennington, MD, said in a…

You must be logged in to read/download the full post.